Booth? By opio?: developing technology to expand the reach of opioid treatment programs into rural and underserved areas. - the goal of this project is to develop a treatment booth with technology…

Ended Project Grant Awarded Last action

Award ID
R44DA056251
Recipient
Awarding agency
Obligated
$3,396,676

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date
Originally
Place of performance
Montana, USA

Award details come from USAspending.gov.

Description

Booth? By opio?: developing technology to expand the reach of opioid treatment programs into rural and underserved areas. - the goal of this project is to develop a treatment booth with technology that allows opioid treatment programs to remotely dispense, either methadone or buprenorphine, under medical observation through telemedicine to a patient in a treatment booth. We believe that robotic automation is the ideal application to perform the same mechanical functions of the nurse at the dosing window. Specifically, these mechanical functions include bottle positioning, capping, labeling, and placing for patient. This would allow nurses to use their clinical skills, serving patients across vast geographic regions, and only using a robot to physically dispense the medication directly to a patient. Technology and automation will create a resilient and agile business model for opioid treatment programs (otps), allowing a contactless patient-nurse experience and a centralized dosing queue which allows clinics to share the dosing window workload across OTP clinics. The drug enforcement agency (DEA) regulates activities and medication storage at otps. That is why our first, and most critical, milestone is to design, build, and compliance test a custom safe that meets our technical needs as well as 21 CFR §1301.72. To determine our technical needs, we must complete the functional requirement specifications for the hardware. After DEA approval, we will develop the software architecture and design, and prototype the end-to-end robotic process from pumping into a bottle, capping, labeling, and placing bottle in a specified location. After that, the complete design engineering, buprenorphine dispenser prototype, software development and the assembly of the alpha device will be completed. The vision of this project is to be the catalyst that allows otps to provide uninterrupted service to patients through a contactless and efficient experience, provide a safe and secure method for methadone inductions via telemedicine, and to allow otps expand services to rural and underserved areas through satellite medication units.

Transactions

Action Obligated Date
Amendment -$6,500
Amendment -$6,500
Amendment $0
Amendment $6,500
Amendment $0
Amendment -$6,500
Amendment $0
Amendment $3
Amendment $3
Amendment $0
Amendment $1,548,615
Amendment $0
Amendment $1,548,615
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $156,220
Original award $156,220
Show all 19

Quick answers

Who received award R44DA056251?

R44DA056251 was awarded to Opio Connect, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 15, 2022.

How much is award R44DA056251 worth?

$3,396,676 has been obligated on R44DA056251.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award